Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Trial, condition or NCT IDCountrySponsorPhaseStatusConditionReset

9 trials match this view; 12 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 657 across 9 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world map Germany source-checked report

Recorded study-start years

202111

202311

202422

202544

202711

Current indexed registry status

Recruiting66

Withdrawn22

Terminated11

Reported research conditions

Opioid Use Disorder99

OCD11

Major Depressive Disorder (MDD)11

Alcohol Use Disorder (AUD)11

Healthy Volunteer11

Migraine11

PTSD11

PTSD - Post Traumatic Stress Disorder11

Addiction11

Tobacco Use Disorder11

Obsessive Compulsive Disorder (OCD)11

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Countries with reported trial locations

United States182182

Canada4141

Switzerland2121

United Kingdom1818

France77

Denmark77

Netherlands66

Czechia55

Ireland55

Sweden44

Israel44

Germany33

Australia33

Spain22

Brazil22

Pakistan22

Portugal22

Belgium22

Poland11

Austria11

New Zealand11

Finland11

Jordan11

Jamaica11

Argentina11

Matching trial records

9 matching registry records. Dates are registry milestones, not promised results announcements.
Trial	Sponsor and phase	Status	Enrollment	Start / primary completion / completion
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial NCT06067737 Opioid Use Disorder	Johns Hopkins University PHASE2	Recruiting Registry updated 2026-07-17	90 ESTIMATED	2024-02-08 2028-07 2029-05
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects NCT06624137 OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer · Migraine · PTSD · PTSD - Post Traumatic Stress Disorder · Addiction · Tobacco Use Disorder · Obsessive Compulsive Disorder (OCD) · Opioid Use Disorder	Yale University Phase not reported	Terminated Registry updated 2026-07-09	5 ACTUAL	2024-12-12 2026-06-14 2026-06-14
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder NCT06810310 Opioid Use Disorder	University of Pennsylvania PHASE2	Recruiting Registry updated 2026-07-09	24 ESTIMATED	2025-12-22 2027-05-01 2027-05-01
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation NCT04161066 Opioid Use Disorder	University of Wisconsin, Madison PHASE1	Recruiting Registry updated 2026-07-07	10 ESTIMATED	2021-01-13 2026-12 2026-12
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) NCT06160284 Opioid Use Disorder	Yale University PHASE1	Recruiting Registry updated 2026-07-07	12 ESTIMATED	2025-05-28 2027-01 2027-01
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial NCT06005662 Opioid Use Disorder	Johns Hopkins University PHASE2	Withdrawn Registry updated 2026-02-23	0 ACTUAL	2027-04 2028-07 2028-07
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment NCT06796062 Opioid Use Disorder	NYU Langone Health PHASE2	Recruiting Registry updated 2026-01-23	480 ESTIMATED	2025-12-17 2029-02 2029-02
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? NCT06786325 Opioid Use Disorder	Anna Rose Childress, Ph.D. PHASE2	Recruiting Registry updated 2025-10-29	36 ESTIMATED	2025-10-07 2027-06 2027-10
A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use NCT05242029 Opioid Use Disorder	Johns Hopkins University PHASE2	Withdrawn Registry updated 2024-02-02	0 ACTUAL	2023-12 2024-02 2024-12

Reported research facilities

Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States

Connecticut Mental Health CenterHamden, Connecticut, United States

West Haven VA Medical CenterWest Haven, Connecticut, United States

University of PennsylvaniaPhiladelphia, Pennsylvania, United States

University of WisconsinMadison, Wisconsin, United States

Yale UniversityNew Haven, Connecticut, United States

Johns Hopkins UniversityBaltimore, Maryland, United States

Duke City Recovery ToolboxAlbuquerque, New Mexico, United States

University of New MexicoAlbuquerque, New Mexico, United States

StartCareBrooklyn, New York, United States

NYU Langone HealthNew York, New York, United States

VIP Community Services, IncThe Bronx, New York, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.